-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Structure Therapeutics, Raises Price Target to $140

Benzinga·01/20/2026 14:15:30
Listen to the news
Guggenheim analyst Seamus Fernandez maintains Structure Therapeutics (NASDAQ:GPCR) with a Buy and raises the price target from $90 to $140.